Humulin N (Nph) Kwikpen (Insulin Human (Rdna))

Humulin N Kwikpen is a pre‑filled pen suspension containing insulin human (NPH) at a strength of 100 U/mL. It is an intermediate‑acting insulin indicated for subcutaneous injection in the European market. The product provides a convenient delivery system for patients requiring basal insulin therapy as part of diabetes management.

Humulin N Kwikpen is prescribed for patients who need long‑acting insulin support to control blood glucose levels. It is commonly used in the following clinical situations:

- Basal insulin therapy for type 1 diabetes mellitus. - Basal insulin therapy for type 2 diabetes mellitus. - Combination with rapid‑acting insulin analogues for a basal‑bolus regimen. - Management of fasting glucose and overnight glycaemic control. - Adjustments during periods of increased insulin resistance, such as illness or steroid therapy.

Adverse reactions to Humulin N Kwikpen vary in frequency and severity.

Common: - Hypoglycaemia (low blood glucose) - Injection site redness, swelling or itching - Lipodystrophy (localized fat loss or accumulation) - Weight gain - Mild nausea

Serious: - Severe hypoglycaemia requiring assistance - Allergic reactions such as urticaria or angioedema - Anaphylaxis (rare) - Persistent hyperglycaemia indicating insulin resistance or dosing error

When using Humulin N Kwikpen, several safety considerations should be observed:

- Monitor blood glucose regularly to detect hypoglycaemia early. - Adjust dose during periods of illness, pregnancy, or when starting/stopping other glucose‑lowering agents. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Educate patients on proper injection technique to minimise lipodystrophy. - Avoid use in individuals with known hypersensitivity to human insulin or protamine. - Review any history of cardiovascular disease, as rapid glucose fluctuations can affect cardiac risk.

Humulin N Kwikpen may interact with other medications, influencing its glucose‑lowering effect.

Avoid: - Concurrent use of other insulin products without dose adjustment, which can cause severe hypoglycaemia. - High‑dose beta‑blockers that may mask hypoglycaemia symptoms.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycaemia risk. - Corticosteroids, which can raise blood glucose and require dose escalation. - Thiazide diuretics and ACE inhibitors, which may affect potassium balance and insulin sensitivity. - Alcohol, as it can cause unpredictable glucose changes. - Certain antidepressants (e.g., MAO inhibitors) that may alter glucose metabolism.